Skip to main content
. 2022 Nov 6;147(4):296–309. doi: 10.1161/CIRCULATIONAHA.122.062779

Figure 1.

Figure 1.

Outline of the AXADIA–AFNET 8 study according to the CONSORT guideline. The included patients and their allocation to the 2 treatment arms are shown in accordance with the CONSORT (Consolidated Standards of Reporting Trials) criteria. AXADIA–AFNET 8 indicates Compare Apixaban and Vitamin K Antagonists in Patients With Atrial Fibrillation and End-Stage Kidney Disease; FU, follow-up; INR, international normalized ratio; and TE, thromboembolism.